{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:05:35Z","timestamp":1791165935296,"version":"4.1.0"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T00:00:00Z","timestamp":1401753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0096829","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T20:22:21Z","timestamp":1401826941000},"page":"e96829","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":108,"title":["A Network Meta-Analysis of the Relative Efficacy of Treatments for Actinic Keratosis of the Face or Scalp in Europe"],"prefix":"10.1371","volume":"9","author":[{"given":"Stefan","family":"Vegter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Tolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2013.134","article-title":"Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study","volume":"133","author":"SC Flohil","year":"2013","journal-title":"J Invest Dermatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial","volume":"115","author":"VD Criscione","year":"2009","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"1","author":"R Marks","year":"1988","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","article-title":"The natural history of actinic keratosis: a systematic review","volume":"169","author":"RN Werner","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"RG Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mjd.2000.103342","article-title":"Epidemiology of actinic keratoses and squamous cell carcinoma","volume":"42","author":"SJ Salasche","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref7","first-page":"1045","article-title":"Frequency and cost of actinic keratosis treatment","volume":"32","author":"L Warino","year":"2006","journal-title":"Dermatol Surg"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"D De Berker","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref9","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"E Stockfleth","year":"2006","journal-title":"Eur J Dermatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"JP Jansen","year":"2008","journal-title":"Value Heal"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"AE Ades","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"DM Caldwell","year":"2005","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"G Lu","year":"2004","journal-title":"Stat Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.12343","article-title":"Network meta-analysis of the outcome \u201cparticipant complete clearance\u201d in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review","volume":"169","author":"K Gupta a","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004415.pub2","article-title":"Interventions for actinic keratoses (Review)","author":"A Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archderm.140.1.41","article-title":"Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials","volume":"140","author":"DJ Piacquadio","year":"2004","journal-title":"Arch Dermatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2008.05.031","article-title":"Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study","volume":"59","author":"D Pariser","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1524-4725.2009.01096.x","article-title":"Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study","volume":"35","author":"R-M Szeimies","year":"2009","journal-title":"Dermatol Surg"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study","volume":"163","author":"R-M Szeimies","year":"2010","journal-title":"Br J Dermatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo","volume":"166","author":"T Dirschka","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up","volume":"157 Suppl","author":"N Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10227-005-0148-6","article-title":"Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies","volume":"9","author":"AK Gupta","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"ref23","unstructured":"University of Bristol, School of Social and Community Medicine. Mixed Treatment Comparisons. (2013). Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.bristol.ac.uk\/social-community-medicine\/projects\/mpes\/mtc\/\" xlink:type=\"simple\">http:\/\/www.bristol.ac.uk\/social-community-medicine\/projects\/mpes\/mtc\/<\/ext-link>."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"G Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"G Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2133.2005.06932.x","article-title":"Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial","volume":"154","author":"T Ooi","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","article-title":"Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial","volume":"140","author":"J Jorizzo","year":"2004","journal-title":"Arch Dermatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"K Gebauer","year":"2003","journal-title":"Australas J Dermatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results","volume":"165","author":"E Stockfleth","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"N Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2009.09040.x","article-title":"Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies","volume":"160","author":"a Hauschild","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"A608","DOI":"10.1016\/j.jval.2013.08.1743","article-title":"Methodological Challenges in Comparing Topical Therapies in Dermatology in the Absence of Head to Head Studies","volume":"16","author":"R Greiner","year":"2013","journal-title":"Value in Health"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1468-3083.2004.01180.x","article-title":"Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin","volume":"19","author":"MB Brown","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref34","first-page":"1625","article-title":"The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan","volume":"57","author":"MP Seed","year":"1997","journal-title":"Cancer Res"},{"key":"ref35","first-page":"157","article-title":"The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001)","volume":"17","author":"C Freemantle","year":"1995","journal-title":"Int J Tissue React"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.2042-7158.1995.tb05820.x","article-title":"Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice","volume":"47","author":"CA Alam","year":"1995","journal-title":"J Pharm Pharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0196-0709(95)90059-4","article-title":"Effect of topical hyaluronic acid on experimental cholesteatoma","volume":"16","author":"SJ White","year":"1995","journal-title":"Am J Otolaryngol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"M Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"M Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"R-M Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"ref41","first-page":"49","article-title":"Selection of the Optimal Pharmaceutical Form of 5-Aminolevulinic Acid and Its Application in the Treatment of Oncologic Diseases","volume":"47","author":"V Armo\u0161kait\u0117","year":"2011","journal-title":"Mededicina (Kaunas)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"MA Stanley","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09546630903341937","article-title":"Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment","volume":"21","author":"RR Kaur","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"AM Glenny","year":"2005","journal-title":"Health Technol Assess"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.jid.5700264","article-title":"Imiquimod for actinic keratosis: systematic review and meta-analysis","volume":"126","author":"G Hadley","year":"2006","journal-title":"J Invest Dermatol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaad.2006.05.030","article-title":"Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials","volume":"55","author":"ME Falagas","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref47","first-page":"30","article-title":"The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation","volume":"70","author":"AK Gupta","year":"2002","journal-title":"Cutis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","article-title":"Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model","volume":"28","author":"ECF Wilson","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09546630902887211","article-title":"An economic evaluation of topical treatments for actinic keratosis","volume":"20","author":"D Muston","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1365-2133.2006.07470.x","article-title":"Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study","volume":"155","author":"C Morton","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1067\/mjd.2002.119649","article-title":"Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study","volume":"47","author":"RM Szeimies","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/bjd.12158","article-title":"Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis","volume":"168","author":"T Dirschka","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"N Korman","year":"2005","journal-title":"Arch Dermatol"},{"key":"ref54","unstructured":"NCT00828568. A Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis. clinicaltrials.gov\/ct2\/show\/NCT00828568."},{"key":"ref55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"J Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","article-title":"Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head","volume":"157","author":"a Alomar","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref57","first-page":"22","article-title":"Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks","volume":"70","author":"J Weiss","year":"2002","journal-title":"Cutis"},{"key":"ref58","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis","volume":"70","author":"J Jorizzo","year":"2002","journal-title":"Cutis"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"JE Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"JK Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"ref61","unstructured":"Solaraze gel: Diclofenac Sodium 3% - package insert."},{"key":"ref62","unstructured":"NCT00700063. A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp). clinicaltrials.gov\/ct2\/show\/NCT00700063."},{"key":"ref63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles","volume":"62","author":"CW Hanke","year":"2010","journal-title":"J Am Acad Dermatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0096829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T17:08:30Z","timestamp":1540314510000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0096829"}},"subtitle":[],"editor":[{"given":"Maarten","family":"Postma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,3]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0096829","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,3]]}}}